Cztery profile pacjentów, w leczeniu których wybieram rupatadynę Artykuł przeglądowy

##plugins.themes.bootstrap3.article.main##

Rafał Pawliczak

Abstrakt

Prezentujemy cztery profile pacjentów, u których można uzyskać szczególne korzyści ze stosowania rupatadyny. Uwzględniamy starsze i najnowsze badania kliniczne.

Pobrania

Dane pobrania nie są jeszcze dostepne

##plugins.themes.bootstrap3.article.details##

Jak cytować
Pawliczak, R. (2022). Cztery profile pacjentów, w leczeniu których wybieram rupatadynę . Alergoprofil, 18(3), 3-5. https://doi.org/10.24292/01.AP.183300922
Dział
THERAPY

Bibliografia

1. Solans A, Izquierdo I, Donado E et al. Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study. Clin Ther. 2008; 30(9): 1639-50.
2. Valero A, Serrano C, Bartrá J et al. Reduction of nasal volume after allergen-induced rhinitis in patients treated with rupatadine: a randomized, cross-over, double-blind, placebo- controlled study. J Investig Allergol Clin Immunol. 2009; 19(6): 488-93.
3. Vasiadi M, Kalogeromitros D, Kempuraj D et al. Rupatadine inhibits proinflammatory mediator secretion from human mast cells triggered by different stimuli. Int Arch Allergy Immunol. 2010; 151(1): 38-45.
4. Mion de Godoy O, Campos RA, Antila M et al. Futura study: evaluation of efficacy and safety of rupatadine fumarate in the treatment of persistent allergic rhinitis. Braz J Otorhinolaryngol. 2009; 75(5): 673-9.
5. Okubo K, Suzuki T, Tanaka A et al. Long-term safety and efficacy of rupatadine in Japanese patients with perennial allergic rhinitis: a 52-week open-label clinical trial. J Drug Assess. 2019; 8(1): 104-14.
6. Valero A, de la Torre F, Castillo JA et al. Safety of rupatadine administered over a period of 1 year in the treatment of persistent allergic rhinitis: a multicentre, open-label study in Spain. Drug Saf. 2009; 32(1): 33-42.
7. Won TB, Kim HG, Kim JW et al. Efficacy and safety of rupatadine fumarate in the treatment of perennial allergic rhinitis: A multicenter, double-blinded, randomized, placebo-controlled, bridging study in Koreans. Asian Pac J Allergy Immunol. 2021.
8. Compalati E, Canonica GW. Efficacy and safety of rupatadine for allergic rhino-conjunctivitis: a systematic review of randomized, double-blind, placebo-controlled studies with meta-analysis. Curr Med Res Opin. 2013; 29(11): 1539-519.
9. Eloy Ph, Tobback L, Imschoot L. Rupatadine relieves allergic rhinitis: a prospective observational study. B-ENT. 2015; 11(1): 11-8.
10. Gonzalez-Nunez V, Bachert C, Mullol J. Rupatadine: global safety evaluation in allergic rhinitis and urticaria. Expert Opin Drug Saf. 2016; 15(10): 1439-48.
11. Katiyar S, Prakash S. Pharmacological profile, efficacy and safety of rupatadine in allergic rhinitis. Prim Care Respir J. 2009; 18(2): 57-68.
12. Shamizadeh S, Brockow K, Ring J. Rupatadine: efficacy and safety of a non-sedating antihistamine with PAF-antagonist effects. Allergo J Int. 2014; 23(3): 87-95.
13. Taubel J, Ferber G, Fernandes S et al. Pharmacokinetics, Safety and Cognitive Function Profile of Rupatadine 10, 20 and 40 mg in Healthy Japanese Subjects: A Randomised Placebo- Controlled Trial. PLoS One. 2016; 11(9): e0163020.